Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + Pembrolizumab in selected solid tumors
NCT05642780Phase 2Active, not recruiting
- Sponsor
- KLUS Pharma
- Start
- Jan 2023
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in Cervical Cancer (CC), urothelial carcinoma (UC), ovarian cancer, prostate cancer (PCa), endometrial cancer (EC), sponsored by KLUS Pharma. Started Jan 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Cervical Cancer (CC)urothelial carcinoma (UC)ovarian cancerprostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05642780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642780.